MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Debt
Debt-to-Equity Ratio-0.44
Current Ratio0.48
Quick Ratio0.43
Price-To-Earnings
Trailing P/E Ratio-0.97
Forward P/E Ratio-1.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.74 million
Price / Sales14.73
Cash FlowN/A
Price / CashN/A
Book Value($1.81) per share
Price / Book-0.62
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-852.27%
Return on EquityN/A
Return on Assets-177.92%
Miscellaneous
Employees250
Outstanding Shares152,990,000
Market Cap$180.53 million
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The biopharmaceutical company earned $3.89 million during the quarter, compared to the consensus estimate of $4.80 million. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
2 Wall Street analysts have issued 1 year target prices for MannKind's stock. Their forecasts range from $1.00 to $4.00. On average, they anticipate MannKind's share price to reach $2.59 in the next twelve months. This suggests a possible upside of 129.2% from the stock's current price. View Analyst Price Targets for MannKind.
What is the consensus analysts' recommendation for MannKind?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MannKind.
What are Wall Street analysts saying about MannKind stock?
Here are some recent quotes from research analysts about MannKind stock:
- 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (7/11/2018)
- 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)
Are investors shorting MannKind?
MannKind saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 30,151,512 shares, a drop of 15.4% from the July 13th total of 35,627,125 shares. Based on an average trading volume of 1,279,392 shares, the short-interest ratio is currently 23.6 days. Currently, 23.9% of the shares of the company are sold short. View MannKind's Current Options Chain.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU) and Progenics Pharmaceuticals (PGNX).
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 41)
- Mr. Steven B. Binder, Chief Financial Officer (Age 55)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)
- Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 51)
Has MannKind been receiving favorable news coverage?
News coverage about MNKD stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a coverage optimism score of 0.20 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for MannKind.
Who are MannKind's major shareholders?
MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.77%), Scopia Capital Management LP (1.09%), Schwab Charles Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.28%), Raymond James & Associates (0.14%) and Rhumbline Advisers (0.09%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.
Which major investors are buying MannKind stock?
MNKD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Scopia Capital Management LP, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Rhumbline Advisers, GSA Capital Partners LLP, Marathon Trading Investment Management LLC and MetLife Investment Advisors LLC. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $1.13.
How big of a company is MannKind?
MannKind has a market capitalization of $180.53 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (NASDAQ MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
